Dormosedan Gel is a drug owned by ORION CORP. It is protected by 2 US drug patents filed from 2025 to 2026. Out of these, 1 patent is active and 1 patent has expired. Details of Dormosedan Gel’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US8309591 | 03 Nov, 2025 | Expired |
Exclusivity Information
Dormosedan Gel holds 1 exclusivity out of which 1 has expired. Details of Dormosedan Gel's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Mar 22, 2013 |
About Dormosedan Gel
Dormosedan Gel is a drug
owned by ORION CORP.
Dormosedan Gel uses
Detomidine Hydrochloride as the active
ingredient.
Active Ingredient:
Dormosedan Gel uses
Detomidine Hydrochloride as the active ingredient.
Check out other Drugs and Companies using
Detomidine Hydrochloride ingredient.